{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:44:10Z","timestamp":1792086250664,"version":"4.4.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA254865"],"award-info":[{"award-number":["P50CA254865"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40257-024-00852-5","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T19:02:36Z","timestamp":1708974156000},"page":"421-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Ryan C.","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"issue":"3","key":"852_CR1","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","volume":"12","author":"KF Grossmann","year":"2022","unstructured":"Grossmann KF, Othus M, Patel SP, et al. Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma. Cancer Discov. 2022;12(3):644\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1141.","journal-title":"Cancer Discov"},{"key":"852_CR2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3145","author":"J Larkin","year":"2023","unstructured":"Larkin J, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3145.","journal-title":"Clin Cancer Res"},{"key":"852_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200214","author":"AMM Eggermont","year":"2022","unstructured":"Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200214.","journal-title":"NEJM Evid."},{"issue":"12","key":"852_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2005493.","journal-title":"N Engl J Med"},{"issue":"10336","key":"852_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(22)00562-1.","journal-title":"Lancet"},{"key":"852_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02583-2","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02583-2.","journal-title":"Nat Med"},{"issue":"9","key":"852_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2211437.","journal-title":"N Engl J Med"},{"key":"852_CR8","doi-asserted-by":"publisher","unstructured":"Zhang X, Ferris L, Faries MB, Luke JJ. Debating sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. J Clin Oncol. 2023;41(26):4204\u20137. https:\/\/doi.org\/10.1200\/JCO.23.00255.","DOI":"10.1200\/JCO.23.00255"},{"key":"852_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDe2200240","author":"RC Augustin","year":"2022","unstructured":"Augustin RC, Luke JJ. Progression\/recurrence-free survival 2 in adjuvant melanoma. N Engl J Med Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDe2200240.","journal-title":"N Engl J Med Evid."},{"issue":"17","key":"852_CR10","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-23-1194","volume":"29","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Luke JJ. PD-1 Monotherapy reigns supreme in adjuvant melanoma\u2026but for how long? Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29(17):3253\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1194.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"5","key":"852_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660\u201370. https:\/\/doi.org\/10.1038\/s41590-022-01141-1.","journal-title":"Nat Immunol"},{"issue":"15_suppl","key":"852_CR12","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2019.37.15_suppl.2512","volume":"37","author":"AMM Eggermont","year":"2019","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. J Clin Oncol. 2019;37(15_suppl):2512. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2512.","journal-title":"J Clin Oncol"},{"issue":"17","key":"852_CR13","doi-asserted-by":"publisher","first-page":"LBA9505","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9505","volume":"41","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. J Clin Oncol. 2023;41(17):LBA9505. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA9505.","journal-title":"J Clin Oncol"},{"issue":"10358","key":"852_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","volume":"400","author":"E Livingstone","year":"2022","unstructured":"Livingstone E, Zimmer L, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet Lond Engl. 2022;400(10358):1117\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(22)01654-3.","journal-title":"Lancet Lond Engl."},{"issue":"11","key":"852_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005684","volume":"10","author":"NI Khushalani","year":"2022","unstructured":"Khushalani NI, Vassallo M, Goldberg JD, et al. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J Immunother Cancer. 2022;10(11): e005684. https:\/\/doi.org\/10.1136\/jitc-2022-005684.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"852_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.22.00533","volume":"41","author":"JS Weber","year":"2023","unstructured":"Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517\u201327. https:\/\/doi.org\/10.1200\/JCO.22.00533.","journal-title":"J Clin Oncol"},{"issue":"3","key":"852_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.22.01770","volume":"41","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Luke JJ. Induction exposure dose of ipilimumab and failure of adjuvant nivolumab plus ipilimumab in melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(3):443\u20136. https:\/\/doi.org\/10.1200\/JCO.22.01770.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"8","key":"852_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105\u201310. https:\/\/doi.org\/10.1245\/s10434-018-6513-7.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"852_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin"},{"issue":"32","key":"852_CR20","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.22.00202","volume":"40","author":"C Garbe","year":"2022","unstructured":"Garbe C, Keim U, Amaral T, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(32):3741\u20139. https:\/\/doi.org\/10.1200\/JCO.22.00202.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"15_suppl","key":"852_CR21","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","volume":"39","author":"JD Wolchok","year":"2021","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol. 2021;39(15_suppl):9506. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9506.","journal-title":"J Clin Oncol"},{"issue":"4","key":"852_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","volume":"19","author":"SM Swetter","year":"2021","unstructured":"Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(4):364\u201376. https:\/\/doi.org\/10.6004\/jnccn.2021.0018.","journal-title":"J Natl Compr Canc Netw."},{"issue":"7","key":"852_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1310460.","journal-title":"N Engl J Med"},{"issue":"1","key":"852_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","volume":"27","author":"DM Bello","year":"2020","unstructured":"Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol. 2020;27(1):15\u201321. https:\/\/doi.org\/10.1245\/s10434-019-07830-w.","journal-title":"Ann Surg Oncol"},{"issue":"16_suppl","key":"852_CR25","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1200\/JCO.2023.41.16_suppl.9504","volume":"41","author":"GV Long","year":"2023","unstructured":"Long GV, Kirkwood JMM, Hoeller C, et al. Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB\/C melanoma (CA209-76K). J Clin Oncol. 2023;41(16_suppl):9504. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9504.","journal-title":"J Clin Oncol"},{"issue":"4","key":"852_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1245\/ASO.2006.05.013","volume":"13","author":"LG Wilke","year":"2006","unstructured":"Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491\u2013500. https:\/\/doi.org\/10.1245\/ASO.2006.05.013.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"852_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178\u201388. https:\/\/doi.org\/10.1038\/s41591-022-01851-x.","journal-title":"Nat Med"},{"issue":"6411","key":"852_CR28","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science"},{"issue":"1","key":"852_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-021-00169-w","volume":"6","author":"C Cui","year":"2021","unstructured":"Cui C, Xu C, Yang W, et al. Ratio of the interferon-\u03b3 signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. NPJ Genom Med. 2021;6(1):1\u201312. https:\/\/doi.org\/10.1038\/s41525-021-00169-w.","journal-title":"NPJ Genom Med"},{"issue":"1","key":"852_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020;8(1):49. https:\/\/doi.org\/10.1186\/s40364-020-00228-x.","journal-title":"Biomark Res."},{"issue":"3","key":"852_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158\u201372. https:\/\/doi.org\/10.1038\/s41577-021-00566-3.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"852_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12967-019-2100-3","volume":"17","author":"D Damotte","year":"2019","unstructured":"Damotte D, Warren S, Arrondeau J, et al. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J Transl Med. 2019;17(1):357. https:\/\/doi.org\/10.1186\/s12967-019-2100-3.","journal-title":"J Transl Med"},{"issue":"8","key":"852_CR33","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930\u201340. https:\/\/doi.org\/10.1172\/JCI91190.","journal-title":"J Clin Investig."},{"issue":"48","key":"852_CR34","doi-asserted-by":"publisher","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","volume":"113","author":"S Spranger","year":"2016","unstructured":"Spranger S, Luke JJ, Bao R, et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA. 2016;113(48):E7759\u201368. https:\/\/doi.org\/10.1073\/pnas.1609376113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"852_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","volume":"12","author":"R Bao","year":"2020","unstructured":"Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020;12(1):90. https:\/\/doi.org\/10.1186\/s13073-020-00787-6.","journal-title":"Genome Med."},{"key":"852_CR36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2241","author":"RC Augustin","year":"2024","unstructured":"Augustin RC, Cai WL, Luke JJ, Bao R. Facts and hopes in using omics to advance combined immunotherapy strategies. Clin Cancer Res Off J Am Assoc Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2241.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"852_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.24.554717","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Newman S, Li A, et al. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. BioRxiv Prepr Serv Biol. 2023. https:\/\/doi.org\/10.1101\/2023.08.24.554717.","journal-title":"BioRxiv Prepr Serv Biol."},{"issue":"8","key":"852_CR38","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","volume":"28","author":"MF Sanmamed","year":"2017","unstructured":"Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;28(8):1988\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdx190.","journal-title":"Ann Oncol"},{"issue":"9","key":"852_CR39","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","volume":"27","author":"A Teijeira","year":"2021","unstructured":"Teijeira A, Garasa S, Ochoa MC, et al. IL8, Neutrophils, and NETs in a collusion against cancer immunity and immunotherapy. Clin Cancer Res. 2021;27(9):2383\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1319.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"852_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen KC, Liu LF, Gupta V, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020;26(5):693\u20138. https:\/\/doi.org\/10.1038\/s41591-020-0860-1.","journal-title":"Nat Med"},{"key":"852_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0394","author":"D Davar","year":"2020","unstructured":"Davar D, Simonelli M, Gutierrez M, et al. 394 Interleukin-8\u2013neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti\u2013PD-(L)1\u2013experienced patients with advanced cancer: initial phase 1 results. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0394.","journal-title":"J Immunother Cancer."},{"issue":"15_suppl","key":"852_CR42","doi-asserted-by":"publisher","first-page":"TPS2681","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2681","volume":"39","author":"L Karapetyan","year":"2021","unstructured":"Karapetyan L, Olson AC, Gooding WE, Bao R, Chmura SJ, Luke JJ. Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):TPS2681. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS2681.","journal-title":"J Clin Oncol"},{"issue":"5","key":"852_CR43","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/bjd.19499","volume":"184","author":"EEP Mulder","year":"2021","unstructured":"Mulder EEP, Dwarkasing JT, Tempel D, et al. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. Br J Dermatol. 2021;184(5):944\u201351. https:\/\/doi.org\/10.1111\/bjd.19499.","journal-title":"Br J Dermatol"},{"key":"852_CR44","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00044","volume":"7","author":"CN Bailey","year":"2023","unstructured":"Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: a SEER collaboration. JCO Precis Oncol. 2023;7: e2300044. https:\/\/doi.org\/10.1200\/PO.23.00044.","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"852_CR45","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","volume":"11","author":"EJ Moding","year":"2021","unstructured":"Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0634.","journal-title":"Cancer Discov"},{"issue":"24","key":"852_CR46","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.21.02615","volume":"40","author":"M Malla","year":"2022","unstructured":"Malla M, Loree JM, Kasi PM, Parikh AR. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2846\u201357. https:\/\/doi.org\/10.1200\/JCO.21.02615.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"852_CR47","doi-asserted-by":"publisher","first-page":"TPS212","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS212","volume":"40","author":"A Dasari","year":"2022","unstructured":"Dasari A, Lin Y, Kopetz S, et al. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). J Clin Oncol. 2022;40(4_suppl):TPS212. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.TPS212.","journal-title":"J Clin Oncol"},{"key":"852_CR48","doi-asserted-by":"publisher","first-page":"S904","DOI":"10.1016\/j.annonc.2022.07.914","volume":"33","author":"GV Long","year":"2022","unstructured":"Long GV, Desai K, Tang T, et al. 788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy (CheckMate 915). Ann Oncol. 2022;33:S904. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.914.","journal-title":"Ann Oncol"},{"issue":"11","key":"852_CR49","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/cncr.34714","volume":"129","author":"RJ Lee","year":"2023","unstructured":"Lee RJ, Luke JJ. Potential of circulating tumor DNA to refine immunotherapy. Cancer. 2023;129(11):1646\u20138. https:\/\/doi.org\/10.1002\/cncr.34714.","journal-title":"Cancer"},{"issue":"11","key":"852_CR50","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.34716","volume":"129","author":"Z Eroglu","year":"2023","unstructured":"Eroglu Z, Krinshpun S, Kalashnikova E, et al. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129(11):1723\u201334. https:\/\/doi.org\/10.1002\/cncr.34716.","journal-title":"Cancer"},{"issue":"16_suppl","key":"852_CR51","doi-asserted-by":"publisher","first-page":"TPS9603","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9603","volume":"40","author":"R Lee","year":"2022","unstructured":"Lee R, Rothwell DG, Jackson R, et al. DETECTION phase II\/III trial: circulating tumor DNA\u2013guided therapy for stage IIB\/C melanoma after surgical resection. J Clin Oncol. 2022;40(16_suppl):TPS9603. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS9603.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"852_CR52","doi-asserted-by":"publisher","first-page":"TPS9587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9587","volume":"39","author":"R Lee","year":"2021","unstructured":"Lee R, Rothwell DG, Chow S, et al. CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma. J Clin Oncol. 2021;39(15_suppl):TPS9587. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS9587.","journal-title":"J Clin Oncol"},{"issue":"2","key":"852_CR53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(2):186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"2","key":"852_CR54","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Mandal\u00e0 M, Ferrucci PF, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(2):212\u201321. https:\/\/doi.org\/10.1200\/JCO.21.02961.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"852_CR55","unstructured":"Washington University School of Medicine. A phase II randomized study of tiragolumab plus atezolizumab versus atezolizumab in the treatment of stage II melanoma patients who are ctDNA-positive following resection. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05060003. Accessed 17 Oct 2023."},{"issue":"1","key":"852_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.2008.17.1777","volume":"27","author":"AA Tarhini","year":"2009","unstructured":"Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in intergroup trial ECOG 1694. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(1):38\u201344. https:\/\/doi.org\/10.1200\/JCO.2008.17.1777.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"852_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/843214","volume":"2014","author":"A Sandru","year":"2014","unstructured":"Sandru A, Panaitescu E, Voinea S, et al. Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. J Skin Cancer. 2014;2014: 843214. https:\/\/doi.org\/10.1155\/2014\/843214.","journal-title":"J Skin Cancer"},{"issue":"4","key":"852_CR58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/CMR.0000000000000269","volume":"26","author":"R H\u00fcgel","year":"2016","unstructured":"H\u00fcgel R, Muendlein A, Volbeding L, et al. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Res. 2016;26(4):354\u201360. https:\/\/doi.org\/10.1097\/CMR.0000000000000269.","journal-title":"Melanoma Res"},{"issue":"4","key":"852_CR59","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","volume":"12","author":"G Brandacher","year":"2006","unstructured":"Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(4):1144\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1966.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"5","key":"852_CR60","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/phpp.12770","volume":"38","author":"L Ding","year":"2022","unstructured":"Ding L, Gosh A, Lee DJ, et al. Prognostic biomarkers of cutaneous melanoma. Photodermatol Photoimmunol Photomed. 2022;38(5):418\u201334. https:\/\/doi.org\/10.1111\/phpp.12770.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"852_CR61","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.12659\/MSM.891327","volume":"20","author":"P Li","year":"2014","unstructured":"Li P, He QY, Luo CQ, Qian LY. Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma. Med Sci Monit Int Med J Exp Clin Res. 2014;20:2472\u20137. https:\/\/doi.org\/10.12659\/MSM.891327.","journal-title":"Med Sci Monit Int Med J Exp Clin Res."},{"key":"852_CR62","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.omtn.2022.02.005","volume":"27","author":"MTD Martino","year":"2022","unstructured":"Martino MTD, Arbitrio M, Caracciolo D, et al. miR-221\/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: a systematic review. Mol Ther Nucl Acids. 2022;27:1191\u2013224. https:\/\/doi.org\/10.1016\/j.omtn.2022.02.005.","journal-title":"Mol Ther Nucl Acids"},{"issue":"3","key":"852_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jdermsci.2010.12.010","volume":"61","author":"H Kanemaru","year":"2011","unstructured":"Kanemaru H, Fukushima S, Yamashita J, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61(3):187\u201393. https:\/\/doi.org\/10.1016\/j.jdermsci.2010.12.010.","journal-title":"J Dermatol Sci"},{"key":"852_CR64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1479-5876-10-185","volume":"10","author":"L Sigalotti","year":"2012","unstructured":"Sigalotti L, Covre A, Fratta E, et al. Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med. 2012;10:185. https:\/\/doi.org\/10.1186\/1479-5876-10-185.","journal-title":"J Transl Med"},{"issue":"6","key":"852_CR65","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/pcmr.12289","volume":"27","author":"NE Thomas","year":"2014","unstructured":"Thomas NE, Slater NA, Edmiston SN, et al. DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. Pigment Cell Melanoma Res. 2014;27(6):1097\u2013105. https:\/\/doi.org\/10.1111\/pcmr.12289.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7047","key":"852_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature03664","volume":"436","author":"LA Garraway","year":"2005","unstructured":"Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436(7047):117\u201322. https:\/\/doi.org\/10.1038\/nature03664.","journal-title":"Nature"},{"issue":"1","key":"852_CR67","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12943-020-01290-7","volume":"19","author":"R Ballotti","year":"2020","unstructured":"Ballotti R, Cheli Y, Bertolotto C. The complex relationship between MITF and the immune system: a melanoma immunotherapy (response) factor? Mol Cancer. 2020;19(1):170. https:\/\/doi.org\/10.1186\/s12943-020-01290-7.","journal-title":"Mol Cancer"},{"issue":"6","key":"852_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131241","volume":"10","author":"A Blancafort","year":"2015","unstructured":"Blancafort A, Gir\u00f3-Perafita A, Oliveras G, et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE. 2015;10(6): e0131241. https:\/\/doi.org\/10.1371\/journal.pone.0131241.","journal-title":"PLoS ONE"},{"issue":"12","key":"852_CR69","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1016\/j.celrep.2017.08.057","volume":"20","author":"A Bagati","year":"2017","unstructured":"Bagati A, Moparthy S, Bianchi-Smiraglia A, et al. Melanoma suppressor functions of the carcinoma oncogene FOXQ1. Cell Rep. 2017;20(12):2820\u201332. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.057.","journal-title":"Cell Rep"},{"key":"852_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2023.1050487","author":"A Cykowska","year":"2023","unstructured":"Cykowska A, Hofmann UK, Tiwari A, Kosnopfel C, Riester R, Danalache M. Biomechanical and biochemical assessment of YB-1 expression in A375 melanoma cell line: exploratory study. Front Mol Med. 2023. https:\/\/doi.org\/10.3389\/fmmed.2023.1050487.","journal-title":"Front Mol Med."},{"issue":"4","key":"852_CR71","doi-asserted-by":"publisher","first-page":"106359","DOI":"10.1016\/j.isci.2023.106359","volume":"26","author":"X Wang","year":"2023","unstructured":"Wang X, Fan D, Yang Y, Gimple RC, Zhou S. Integrative multi-omics approaches to explore immune cell functions: challenges and opportunities. iScience. 2023;26(4):106359. https:\/\/doi.org\/10.1016\/j.isci.2023.106359.","journal-title":"iScience."},{"issue":"1","key":"852_CR72","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/s41467-022-30549-4","volume":"13","author":"A Ma","year":"2022","unstructured":"Ma A, Xin G, Ma Q. The use of single-cell multi-omics in immuno-oncology. Nat Commun. 2022;13(1):2728. https:\/\/doi.org\/10.1038\/s41467-022-30549-4.","journal-title":"Nat Commun"},{"issue":"10","key":"852_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004867","volume":"10","author":"R Sun","year":"2022","unstructured":"Sun R, Lerousseau M, Briend-Diop J, et al. Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. J Immunother Cancer. 2022;10(10): e004867. https:\/\/doi.org\/10.1136\/jitc-2022-004867.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"852_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001752","volume":"9","author":"RR Colen","year":"2021","unstructured":"Colen RR, Rolfo C, Ak M, et al. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021;9(4): e001752. https:\/\/doi.org\/10.1136\/jitc-2020-001752.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"852_CR75","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3390\/cancers12123574","volume":"12","author":"V Ghini","year":"2020","unstructured":"Ghini V, Laera L, Fantechi B, et al. Metabolomics to assess response to immune checkpoint inhibitors in patients with non-small-cell lung cancer. Cancers. 2020;12(12):3574. https:\/\/doi.org\/10.3390\/cancers12123574.","journal-title":"Cancers"},{"issue":"16","key":"852_CR76","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1158\/1078-0432.CCR-19-3748","volume":"28","author":"AS Szalay","year":"2022","unstructured":"Szalay AS, Taube JM. Data-rich spatial profiling of cancer tissue: astronomy informs pathology. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(16):3417\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3748.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"8","key":"852_CR77","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.ccell.2021.07.004","volume":"39","author":"EF Davis-Marcisak","year":"2021","unstructured":"Davis-Marcisak EF, Deshpande A, Stein-O\u2019Brien GL, et al. From bench to bedside: single-cell analysis for cancer immunotherapy. Cancer Cell. 2021;39(8):1062\u201380. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.004.","journal-title":"Cancer Cell"},{"issue":"1","key":"852_CR78","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/1078-0432.CCR-20-2415","volume":"27","author":"P Johannet","year":"2021","unstructured":"Johannet P, Coudray N, Donnelly DM, et al. Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(1):131\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2415.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"1","key":"852_CR79","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1038\/s41467-022-31535-6","volume":"13","author":"J Kong","year":"2022","unstructured":"Kong J, Ha D, Lee J, et al. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun. 2022;13(1):3703. https:\/\/doi.org\/10.1038\/s41467-022-31535-6.","journal-title":"Nat Commun"},{"issue":"7","key":"852_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006788","volume":"11","author":"F Wei","year":"2023","unstructured":"Wei F, Azuma K, Nakahara Y, et al. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. J Immunother Cancer. 2023;11(7): e006788. https:\/\/doi.org\/10.1136\/jitc-2023-006788.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"852_CR81","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandal\u00e0 M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(21)00065-6.","journal-title":"Lancet Oncol"},{"issue":"19","key":"852_CR82","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"issue":"9","key":"852_CR83","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/jnci\/djad081","volume":"115","author":"H Helgadottir","year":"2023","unstructured":"Helgadottir H, Ny L, Ullenhag GJ, et al. Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study. J Natl Cancer Inst. 2023;115(9):1077\u201384. https:\/\/doi.org\/10.1093\/jnci\/djad081.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"852_CR84","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/cncr.34086","volume":"128","author":"B George","year":"2022","unstructured":"George B, Kurzrock R. Progression-free survival 2: is it ready for prime time? Cancer. 2022;128(7):1361\u20132. https:\/\/doi.org\/10.1002\/cncr.34086.","journal-title":"Cancer"},{"issue":"7","key":"852_CR85","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cncr.34085","volume":"128","author":"RG Woodford","year":"2022","unstructured":"Woodford RG, Zhou DDX, Kok PS, et al. The validity of progression-free survival 2 as a surrogate trial end point for overall survival. Cancer. 2022;128(7):1449\u201357. https:\/\/doi.org\/10.1002\/cncr.34085.","journal-title":"Cancer"},{"issue":"2","key":"852_CR86","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1245\/s10434-019-07963-y","volume":"27","author":"A Livingstone","year":"2020","unstructured":"Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for immunotherapy in melanoma: a systematic review. Ann Surg Oncol. 2020;27(2):571\u201384. https:\/\/doi.org\/10.1245\/s10434-019-07963-y.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"852_CR87","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/cancers15020409","volume":"15","author":"MM De Meza","year":"2023","unstructured":"De Meza MM, Blokx WAM, Bonenkamp JJ, et al. Adjuvant BRAF-MEK inhibitors versus anti PD-1 therapy in stage III melanoma: a propensity-matched outcome analysis. Cancers. 2023;15(2):409. https:\/\/doi.org\/10.3390\/cancers15020409.","journal-title":"Cancers"},{"issue":"1","key":"852_CR88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","volume":"24","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023;24(1):33\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(22)00687-8.","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"852_CR89","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1200\/JCO.2022.40.16_suppl.9516","volume":"40","author":"A Ribas","year":"2022","unstructured":"Ribas A, Ferrucci PF, Atkinson V, et al. Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E\/K-mutant melanoma: long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. J Clin Oncol. 2022;40(16_suppl):9516. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9516.","journal-title":"J Clin Oncol"},{"issue":"13","key":"852_CR90","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.21.01601","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Robert C, et al. Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(13):1428\u201338. https:\/\/doi.org\/10.1200\/JCO.21.01601.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"1","key":"852_CR91","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"key":"852_CR92","unstructured":"Bristol-Myers S. A phase 3, randomized, double-blind study of adjuvant immunotherapy with nivolumab + relatlimab fixed-dose combination versus nivolumab monotherapy after complete resection of stage III-IV melanoma. clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05002569. Accessed 14 Sept 2022."},{"issue":"16_suppl","key":"852_CR93","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.1200\/JCO.2023.41.16_suppl.9501","volume":"41","author":"O Hamid","year":"2023","unstructured":"Hamid O, Lewis KD, Weise AM, et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: post adjuvant PD-1 analysis. J Clin Oncol. 2023;41(16_suppl):9501. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9501.","journal-title":"J Clin Oncol"},{"issue":"8_Supplement","key":"852_CR94","doi-asserted-by":"publisher","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2023-CT002","volume":"83","author":"R Dummer","year":"2023","unstructured":"Dummer R, Robert C, Scolyer RA, et al. Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma. Cancer Res. 2023;83(8_Supplement):CT002. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-CT002.","journal-title":"Cancer Res."},{"issue":"8","key":"852_CR95","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2021-1286","volume":"18","author":"AM Eggermont","year":"2022","unstructured":"Eggermont AM, Ascierto PA, Khushalani NI, et al. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III\/IV melanoma at high risk for recurrence. Future Oncol Lond Engl. 2022;18(8):903\u201313. https:\/\/doi.org\/10.2217\/fon-2021-1286.","journal-title":"Future Oncol Lond Engl."},{"issue":"16_suppl","key":"852_CR96","doi-asserted-by":"publisher","first-page":"TPS9611","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9611","volume":"41","author":"GV Long","year":"2023","unstructured":"Long GV, Eggermont AM, Gershenwald JE, et al. KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II\u2013IV melanoma. J Clin Oncol. 2023;41(16_suppl):TPS9611. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS9611.","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"852_CR97","doi-asserted-by":"publisher","first-page":"LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","volume":"41","author":"A Khattak","year":"2023","unstructured":"Khattak A, Weber JS, Meniawy T, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial. J Clin Oncol. 2023;41(17_suppl):LBA9503. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA9503.","journal-title":"J Clin Oncol"},{"key":"852_CR98","doi-asserted-by":"publisher","unstructured":"Van Akkooi ACJ, Hauschild A, Long GV, et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB\/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. J Clin Oncol. 2023;41(16_suppl):TPS9601. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS9601.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9601"},{"issue":"7","key":"852_CR99","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/jnci\/djaa216","volume":"113","author":"M Krishnamoorthy","year":"2021","unstructured":"Krishnamoorthy M, Lenehan JG, Maleki VS. Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges. J Natl Cancer Inst. 2021;113(7):823\u201332. https:\/\/doi.org\/10.1093\/jnci\/djaa216.","journal-title":"J Natl Cancer Inst"},{"key":"852_CR100","doi-asserted-by":"publisher","first-page":"S1288","DOI":"10.1016\/j.annonc.2023.10.042","volume":"34","author":"S Patel","year":"2023","unstructured":"Patel S, Othus M, Wright P, et al. LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801. Ann Oncol. 2023;34:S1288. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.042.","journal-title":"Ann Oncol"},{"issue":"2","key":"852_CR101","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256\u201363. https:\/\/doi.org\/10.1038\/s41591-020-01211-7.","journal-title":"Nat Med"},{"issue":"16_suppl","key":"852_CR102","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.1200\/JCO.2022.40.16_suppl.9501","volume":"40","author":"CU Blank","year":"2022","unstructured":"Blank CU, Reijers ILM, Saw RPM, et al. Survival data of PRADO: a phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2022;40(16_suppl):9501. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9501.","journal-title":"J Clin Oncol"},{"issue":"5","key":"852_CR103","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221952","volume":"220","author":"ILM Reijers","year":"2023","unstructured":"Reijers ILM, Rao D, Versluis JM, et al. IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma. J Exp Med. 2023;220(5): e20221952. https:\/\/doi.org\/10.1084\/jem.20221952.","journal-title":"J Exp Med"},{"key":"852_CR104","doi-asserted-by":"publisher","unstructured":"Lucas MW, Lijnsvelt J, Pulleman S, et al. The NADINA trial: a multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. J Clin Oncol. 2022;40(16_suppl):TPS9605. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS9605.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605"},{"issue":"7934","key":"852_CR105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611(7934):155\u201360. https:\/\/doi.org\/10.1038\/s41586-022-05368-8.","journal-title":"Nature"},{"key":"852_CR106","unstructured":"Melanoma Institute Australia. A phase 2, open label, single arm, clinical trial of neoadjuvant relatlimab and nivolumab in high risk, clinical stage II cutaneous melanoma. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05418972. Accessed 31 Dec 2022."},{"issue":"3","key":"852_CR107","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1172\/JCI66236","volume":"123","author":"DA Knight","year":"2013","unstructured":"Knight DA, Ngiow SF, Li M, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Investig. 2013;123(3):1371\u201381. https:\/\/doi.org\/10.1172\/JCI66236.","journal-title":"J Clin Investig"},{"issue":"9","key":"852_CR108","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.4161\/onci.21940","volume":"1","author":"M Donia","year":"2012","unstructured":"Donia M, Fagone P, Nicoletti F, et al. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology. 2012;1(9):1476\u201383. https:\/\/doi.org\/10.4161\/onci.21940.","journal-title":"Oncoimmunology."},{"key":"852_CR109","unstructured":"Mayo Clinic. Neoadjuvant therapy for patients with high risk stage III melanoma: a pilot clinical trial. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT03554083. Accessed 31 Dec 2022."},{"key":"852_CR110","doi-asserted-by":"publisher","first-page":"1107307","DOI":"10.3389\/fonc.2023.1107307","volume":"13","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Cioli E, Chiarion-Sileni V, et al. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study. Front Oncol. 2023;13:1107307. https:\/\/doi.org\/10.3389\/fonc.2023.1107307.","journal-title":"Front Oncol"},{"issue":"16_suppl","key":"852_CR111","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2022.40.16_suppl.9503","volume":"40","author":"GV Long","year":"2022","unstructured":"Long GV, Carlino MS, Au-Yeung G, et al. NeoTrio: randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy. J Clin Oncol. 2022;40(16_suppl):9503\u20139503. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9503.","journal-title":"J Clin Oncol"},{"key":"852_CR112","doi-asserted-by":"publisher","unstructured":"Tarhini A, Eroglu Z, Sarnaik A, et al. 617 Neoadjuvant intratumoral TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0617.","DOI":"10.1136\/jitc-2022-SITC2022.0617"},{"key":"852_CR113","unstructured":"Incorporated OM. OncoSec announces clinical data of the KEYNOTE-695 TRIAL ASSESSING TAVOTM-EP in combination with KEYTRUDA\u00ae (pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment. https:\/\/www.prnewswire.com\/news-releases\/oncosec-announces-clinical-data-of-the-keynote-695-trial-assessing-tavo-ep-in-combination-with-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-refractory-to-anti-pd-1-treatment-301787777.html. Accessed 18 Oct 2023."},{"key":"852_CR114","unstructured":"Philogen S.p.A. A pivotal phase iii, open-label, randomized, controlled multi-center study of the efficacy of L19IL2\/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B\/C melanoma patients. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT02938299. Accessed 31 Dec 2022."},{"key":"852_CR115","unstructured":"Idera pharmaceuticals shares positive results from investigator-sponsored trial in melanoma patients at Amsterdam UMC\u2014enrollment stopped early for efficacy. BioSpace. Accessed 3 Nov 2023. https:\/\/www.biospace.com\/article\/idera-pharmaceuticals-shares-positive-results-from-investigator-sponsored-trial-in-melanoma-patients-at-amsterdam-umc-enrollment-stopped-early-for-efficacy-\/."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00852-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T19:09:27Z","timestamp":1714936167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00852-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00852-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"7 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by National Institutes of Health (NIH) Grant UM1CA186690 (JJL), P50CA254865 (JJL), and in part by the National Cancer Institute (NCI) through the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center\u2019s Cancer Center Support Grant (CCSG) award (P30CA047904).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RCA: None. JJL: Data and safety monitoring board (DSMB): AbbVie, Immutep, and Evaxion; scientific advisory board: (no stock) 7 Hills, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, Pyxis, STipe, and Tempest; consultancy with compensation: AbbVie, Bayer, Bristol-Myers Squibb, Castle, CHECKMATE, Codiak, Crown, Day One, Duke St, EMD Serono, Endeavor, Flame, Genentech, Gilead, Glenmark, HotSpot, Kadmon, Janssen, Ikena, Immunocore, Incyte, IO Biotech, Macrogenics, Merck, Nektar, Novartis, Partner, Pfizer, Regeneron, Roivant, Servier, STINGthera, Synlogic, and Synthekine; research support (all to institution for clinical trials): AbbVie, Astellas, Astrazeneca, Bristol-Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, and Xencor; patents (both provisional): Serial #15\/612,657 (cancer immunotherapy), PCT\/US18\/36052 (microbiome biomarkers for anti-PD-1\/PD-L1 responsiveness: diagnostic, prognostic and therapeutic uses thereof).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials\/code availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"RCA and JJL conceived of the paper, wrote the manuscript, and approved the final version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}}]}}